However, although these cancers are clinically managed as distinct entities, the literature findings of co-occurring driver genes among these three cancers, such as TP53, PI3K pathway members, and GATA3 genes (Kandoth et al., 2013; Neapolitan et al., 2015; Hoadley et al., 2018; Liu et al., 2018; Sanchez-Vega et al., 2018), led us to combine these three female-specific and hormone-sensitive cancers. Here, TP53 is linked to cancer.